National Sickle Cell and Thalassemia Blood Group Genotyping Programme
The proposed 12-month programme will enable genotyping of blood groups by NHS BT in current patients (up to 17,800 patients) with either sickle cell or thalassemia. Additional information: Direct Award justified under Reg 32 as lack of competition due to technical reasons. NHSBT are the only organisation capable of delivering the scope of servcies
Buyer
NHS England
Value
£854,000
Published
26 Sept 2023
Closes
10 Jul 2023
Procurement details
Source
Contracts Finder
Region
London
Procurement method
Other
Category
Services
Contract starts
27 Sept 2023
Contract ends
27 Jul 2024
CPV classifications
85100000
Health services
Lots
Lot default National Sickle Cell and Thalassemia Blood Group Genotyping Programme
£854,000
The proposed 12-month programme will enable genotyping of blood groups by NHS BT in current patients (up to 17,800 patients) with either sickle cell or thalassemia. Additional information: Direct Award justified under Reg 32 as lack of competition due to technical reasons. NHSBT are the only organisation capable of delivering the scope of servcies
Delivery: England · United Kingdom, England, United Kingdom
Documents
Unlock document linkAwarded contract notice on Contracts Finder
26 Sept 2023
Awarded contract notice on Contracts Finder
Award notice · Web page
BC17023 SICKLECELL THALASSEMIA NHSE NHSBT Services TsCs. FINAL CLEAN FULLY SIGNED & DATED REDACTED
Not provided
BC17023 SICKLECELL THALASSEMIA NHSE NHSBT Services TsCs. FINAL CLEAN FULLY SIGNED & DATED REDACTED
Contains public sector information licensed under the Open Government Licence v3.0.